Park Dental Partners Inc. (PARK) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Park Dental Partners Inc. (NASDAQ: PARK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $20.06 (-2.79% 1D, market cap $95.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PARK ranks #366 in composite RQD confidence.
Within the Health Care sector (Misc Health and Biotechnology Services), PARK carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CCEL (Cryo-Cell International Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 18.2%, cap $41.8M) and VMD (Viemed Healthcare Inc.) posts a C+ grade (69/100 RQD, P/E 24.6x, ROIC 13.0%, cap $379.0M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).
Per PARK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002069604), Park Dental Partners Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $178.2M in total assets and $10.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
FRED Regime × Technicals: 61% of 52W Range • RSI-14 at 57.9 (BULLISH MOMENTUM)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
While PARK currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.31) and Max Pain ($21.06) forces dealer call-delta covering toward $28.13.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Park Dental Partners Inc. (PARK) dropped -2.79% to $20.06, trading at 61% of its 52-week range ($9.53 – $26.79). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
MINNEAPOLIS, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will report its financial results for the quarter ended September
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PARK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PARK. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Park Dental Partners Inc. (PARK) ranks #366 by composite RQD confidence (49/100, grade D) and #665 by equity capitalization ($95.4M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with PARK at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PARK
ACTIVE
Park Dental Partners Inc. | D | 49/100 | — | — | — | -2.79% | $95.4M | Benchmark Subject |
| CCEL Cryo-Cell International Inc. | C | 64/100 | — | — | 18.2% | +1.17% | $41.8M | /ccel-vs-park → |
| VMD Viemed Healthcare Inc. | C+ | 69/100 | 24.6x | 57.5% | 13.0% | -0.40% | $379.0M | /vmd-vs-park → |
| NIVF NewGenIvf Group Limited (Class A) | E | 22/100 | — | — | -32.8% | -5.00% | $11.3M | /nivf-vs-park → |
| AGL agilon health inc. | E | 28/100 | — | — | -35.0% | -5.56% | $1.44B | /agl-vs-park → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Park Dental Partners Inc. (PARK) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, PARK closed FY2025 with $178.2M in total assets against $10.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $178.2M | $10.1M |
As of 2026-11-01, Park Dental Partners Inc. (NASDAQ: PARK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $20.06 (-2.79% 1D, market cap $95.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PARK ranks #366 in composite RQD confidence.
Within the Health Care sector (Misc Health and Biotechnology Services), PARK carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CCEL (Cryo-Cell International Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 18.2%, cap $41.8M) and VMD (Viemed Healthcare Inc.) posts a C+ grade (69/100 RQD, P/E 24.6x, ROIC 13.0%, cap $379.0M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).
Per PARK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002069604), Park Dental Partners Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $178.2M in total assets and $10.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PARK last traded at $20.06 (-2.79% on volume of 69,368 shares), positioning the stock -1.23% below its 50-day simple moving average ($20.31) and +5.69% above its 200-day simple moving average ($18.98). Across its 52-week range of $9.53 to $26.79, PARK sits at the 61.0% percentile with a 14-day RSI of 57.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($17.55 to $22.57).
Why PARK Stock dropped -2.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.